Summary
Thirty-one patients with previously untreated advanced non-small cell lung cancer were treated with mitomycin C (10 mg/m2, day 1), vinblastine (5 mg/m2, days 1 and 15), and cisplatin (80 mg/m2, day 1). Combination chemotherapy was repeated at 4-week intervals until disease progression or unacceptable toxicity. The overall response rate was 52.0%, with a median survival time of 8 months. The median duration of response was 16 weeks (range, 7–49 weeks), and 23% of the patients survived for more than 1 year. Toxicity included moderate myelosuppression, mild nephropathy, and severe nausea and vomiting. This combination therapy of anticancer agents appears to have antitumor activity, but not to have satisfactory therapeutic activity for advanced non-small cell lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson P, Spain R, Speer J, Zinn C, Martz D, Kersey D, Schiller J, Salata J, Harr JP (1984) Mitomycin-C (M), cis-platinum (P) and vinblastine (V) infusion (M-PV) in combined modality therapy (CMT) of stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 3:217
Bakowsky MT, Crouch JC (1983) Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat Rev 10:159
Baraniewski H, Reddy SK, Ayulo MA, Takita H (1984) Continuous six-day infusion chemotherapy in the treatment of non-small cell lung cancers. Proc Am Soc Clin Oncol 3:225
Bitran JD, Desser RK, Shapiro CM (1981) Velban and cisplatin in the treatment of refractory stage IIIMI non-small cell bronchogenic carcinoma (NSCBC). Proc AACR/ASCO 22:501
Butler TP, Macdonald JS, Smith FP, Smith LF, Woolley PV, Schein PS (1979) 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung. Cancer 43:1183
Eagan RT, Fleming TR, Schoonover V (1979) Evaluation of response criteria in advanced lung cancer. Cancer 44:1125
Esseesse I, Babott D, Rothenberg SP, Maguire M, Abrams R (1984) cis-Diamminedichloroplatinum (II) (CP) and vinblastine (VBL) treatment of advanced non-small cell lung cancer (NSCLC): development of a severe debilitation syndrome (SDS). Proc Am Soc Clin Oncol 3:216
Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986) Longterm survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 4:702
Folman R, Rosman M, Auerbach S (1984) Mitomycin-C, vinblastine, and cis-platinum (MVP) in the combined modality treatment of non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 3:232
Gralla RJ, Capser ES, Kelsen DP, Braun DW Jr, Dukeman ME, Martini N, Young CW, Golbey RB (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95:414
Griffin JP, Niell HB (1984) Mitomycin, vinblastine and cisplatin in the treatment of stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 3:211
Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High-dose cis-platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372
Kris MG, Gralla RJ, Kalman LA, Kelsen DP, Casper ES, Burke MT, Groshen S, Cibas IR, Bagin R, Heelan RT (1985) Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 69:387
Kris MG, Gralla RJ, Wertheim MS, Kelsen DP, O'Connell JP, Burke MT, Fiore JJ, Cibas IR, Heelan RT (1986) Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 70:1091
Miller TP, McMahon LJ, Livingston RB (1980) Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine, and mitomycin C (FOMi). Cancer Treat Rep 64:1241
Miller TP, Vance RB, Ahmann FR, Rodney SR (1986) Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a South-West Oncology Group study. Cancer Treat Rep 70:1101
Panettiere FJ, Talley RW, Torres J, Lane M (1976) Porfiromycin in the management of epidermoid and transitional cell cancer: a phase II study. Cancer Treat Rep 60:907
Ruckdeschel JC, Finkelstein DM, Mason BA, Creech RH (1985) Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V-a randomized comparison of four cisplatin-containing regimens. J Clin Oncol 3:72
Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S (1986) A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4:14
Samson MK, Comis RL, Baker LH, Ginsberg S, Fraile RJ, Crooke ST (1978) Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 62:163
Schulman P, Budman DR, Weiselberg L, Vinciguerra V, Degnan TJ (1983) Phase II trial of mitomycin, vinblastine and cisplatin (MVP) in non-small-cell bronchogenic carcinoma. Cancer Treat Rep 67:943
Stoopler MB, Jaretzki III A, Rakowski TJ, Garrett J, Ellison RR (1982) Vinblastine (VLB) and cis-dichlorodiammineplatinum (DDP) combination chemotherapy in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1: 141
Tyson LB, Gralla RJ, Clark RA, Kris MG (1983) Combination antiemetic trials with metoclopramide (MCP). Proc Am Soc Clin Oncol 2: 91
Woodcock TM, Blumenreich MS, Richman SP, Kubota TT, Gentile PS, Allegra JC (1983) Combination chemotherapy with cis-diammine dichloroplatinum and vinblastine in advanced non-small cell lung cancer. J Clin Oncol 1:247
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nomura, F., Shimokata, K., Saito, H. et al. Mitomycin C, vinblastine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 20, 324–326 (1987). https://doi.org/10.1007/BF00262585
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262585